title: Evidence of positive selection at codon sites localized in extracellular domains of mammalian CC motif chemokine receptor proteins.
abstract: BACKGROUND
  CC chemokine receptor proteins (CCR1 through CCR10) are seven-transmembrane G-protein coupled receptors whose signaling pathways are known for their important roles coordinating immune system responses through targeted trafficking of white blood cells. In addition, some of these receptors have been identified as fusion proteins for viral pathogens: for example, HIV-1 strains utilize CCR5, CCR2 and CCR3 proteins to obtain cellular entry in humans. The extracellular domains of these receptor proteins are involved in ligand-binding specificity as well as pathogen recognition interactions.In mammals, the majority of chemokine receptor genes are clustered together; in humans, seven of the ten genes are clustered in the 3p21-24 chromosome region. Gene conversion events, or exchange of DNA sequence between genes, have been reported in chemokine receptor paralogs in various mammalian lineages, especially between the cytogenetically closely located pairs CCR2/5 and CCR1/3. Datasets of mammalian orthologs for each gene were analyzed separately to minimize the potential confounding impact of analyzing highly similar sequences resulting from gene conversion events.Molecular evolution approaches and the software package Phylogenetic Analyses by Maximum Likelihood (PAML) were utilized to investigate the signature of selection that has acted on the mammalian CC chemokine receptor (CCR) gene family. The results of neutral vs. adaptive evolution (positive selection) hypothesis testing using Site Models are reported. In general, positive selection is defined by a ratio of nonsynonymous/synonymous nucleotide changes (dN/dS, or omega) >1.
  
  
  RESULTS
  Of the ten mammalian CC motif chemokine receptor sequence datasets analyzed, only CCR2 and CCR3 contain amino acid codon sites that exhibit evidence of positive selection using site based hypothesis testing in PAML. Nineteen of the twenty codon sites putatively indentified as likely to be under positive selection code for amino acid residues located in extracellular domains of the receptor protein products.
  
  
  CONCLUSIONS
  These results suggest that amino acid residues present in intracellular and membrane-bound domains are more selectively constrained for functional signal transduction and homo- or heterodimerization, whereas amino acid residues in extracellular domains of these receptor proteins evolve more quickly, perhaps due to heightened selective pressure resulting from ligand-binding and pathogen interactions of extracellular domains.
authors.affiliation: Department of Biological Sciences, Idaho State University, Pocatello, 83209, USA. kmetzger@umn.edu
authors.forename: Kelsey J
authors.initials: KJ
authors.lastname: Metzger
authors.forename: Michael A
authors.initials: MA
authors.lastname: Thomas
mesh_terms: D000818:Animals; D003062:Codon; D006801:Humans; D054388:Receptors, CCR / Q000737:chemistry / Q000235:genetics* / Q000276:immunology; D012641:Selection, Genetic
chemical_list: D003062:Codon; D054388:Receptors, CCR
references.citation: Crit Rev Oral Biol Med. 1995;6(2):109-18
references.pmid: 7548618
references.citation: J Struct Funct Genomics. 2003;3(1-4):201-12
references.pmid: 12836699
references.citation: J Clin Invest. 1997 Aug 1;100(3):497-502
references.pmid: 9239395
references.citation: Trends Genet. 2000 Jun;16(6):276-7
references.pmid: 10827456
references.citation: Genomics. 2007 Aug;90(2):213-24
references.pmid: 17544254
references.citation: ACS Chem Biol. 2007 Nov 20;2(11):735-44
references.pmid: 18030990
references.citation: Gene. 2000 Apr 4;246(1-2):239-45
references.pmid: 10767545
references.citation: Mol Biol Evol. 2005 Apr;22(4):1107-18
references.pmid: 15689528
references.citation: Mol Pharmacol. 2002 Sep;62(3):729-36
references.pmid: 12181451
references.citation: Int J Immunogenet. 2007 Oct;34(5):321-4
references.pmid: 17845301
references.citation: J Mol Model. 2003 Oct;9(5):329-36
references.pmid: 14517611
references.citation: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006 Nov;150(2):191-204
references.pmid: 17426779
references.citation: Annu Rev Immunol. 1997;15:675-705
references.pmid: 9143704
references.citation: Nucleic Acids Res. 2003 Jul 1;31(13):3856-8
references.pmid: 12824436
references.citation: Science. 1996 Jun 28;272(5270):1955-8
references.pmid: 8658171
references.citation: Syst Biol. 2007 Aug;56(4):673-84
references.pmid: 17661234
references.citation: J Acquir Immune Defic Syndr. 2005 Apr 15;38(5):509-17
references.pmid: 15793360
references.citation: Mol Biol Evol. 2001 Aug;18(8):1585-92
references.pmid: 11470850
references.citation: Curr Biol. 2007 Apr 3;17(7):R230-1
references.pmid: 17407748
references.citation: J Virol. 2003 Nov;77(22):12310-8
references.pmid: 14581567
references.citation: Mol Immunol. 2006 Mar;43(8):1221-31
references.pmid: 16102831
references.citation: Curr Med Chem. 2008;15(13):1297-304
references.pmid: 18537609
references.citation: Mol Biol Evol. 2007 Aug;24(8):1586-91
references.pmid: 17483113
references.citation: Immunogenetics. 2006 Jun;58(5-6):494-501
references.pmid: 16596402
references.citation: J Biol Chem. 1999 Jun 4;274(23):16228-34
references.pmid: 10347178
references.citation: J Clin Immunol. 2006 Sep;26(5):476-84
references.pmid: 16865553
references.citation: Biosci Rep. 2006 Oct;26(5):325-39
references.pmid: 17024562
references.citation: J Hered. 2008 Sep-Oct;99(5):500-11
references.pmid: 18502735
references.citation: Bioinformatics. 1998;14(9):817-8
references.pmid: 9918953
references.citation: Bioinformatics. 2006 Dec 1;22(23):2971-2
references.pmid: 17021158
references.citation: Comput Appl Biosci. 1997 Oct;13(5):555-6
references.pmid: 9367129
references.citation: J Biol Chem. 1998 Aug 7;273(32):19972-6
references.pmid: 9685332
references.citation: J Biol Chem. 2003 Feb 14;278(7):5179-87
references.pmid: 12466283
references.citation: J Infect Dis. 2008 Jan 15;197(2):262-5
references.pmid: 18179388
references.citation: Syst Biol. 1998 Mar;47(1):125-33
references.pmid: 12064232
references.citation: Cytokine. 2006 Feb 7;33(3):171-8
references.pmid: 16524739
references.citation: J Exp Med. 2006 Jan 23;203(1):35-40
references.pmid: 16418398
references.citation: Virology. 2004 Nov 10;329(1):109-18
references.pmid: 15476879
references.citation: Infect Agents Dis. 1994 Apr-Jun;3(2-3):137-54
references.pmid: 7812652
references.citation: APMIS. 2004 Jul-Aug;112(7-8):481-95
references.pmid: 15563311
references.citation: Int J Immunogenet. 2007 Jun;34(3):153-6
references.pmid: 17504503
references.citation: Science. 1994 Mar 25;263(5154):1762-7
references.pmid: 8134838
references.citation: Trends Immunol. 2006 Jul;27(7):308-12
references.pmid: 16753343
references.citation: Hum Mol Genet. 1999;8(10):1939-45
references.pmid: 10469847
references.citation: J Mol Evol. 2009 Jun;68(6):679-87
references.pmid: 19471989
references.citation: Front Biosci (Landmark Ed). 2009 Jan 01;14:540-51
references.pmid: 19273084
references.citation: J Biol Chem. 1999 Nov 5;274(45):32055-62
references.pmid: 10542238
references.citation: J Biol Chem. 2000 Jun 23;275(25):18946-61
references.pmid: 10747879
references.citation: J Leukoc Biol. 1997 Jul;62(1):20-9
references.pmid: 9225988
references.citation: Eur J Immunol. 2005 Apr;35(4):1301-10
references.pmid: 15739168
references.citation: Cardiovasc Res. 2008 May 1;78(2):250-6
references.pmid: 18252760
references.citation: J Acquir Immune Defic Syndr. 2004 Apr 15;35(5):446-54
references.pmid: 15021309
references.citation: J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):309-13
references.pmid: 15076247
references.citation: Annu Rev Immunol. 2000;18:217-42
references.pmid: 10837058
references.citation: Annu Rev Pharmacol Toxicol. 2002;42:469-99
references.pmid: 11807180
references.citation: Biochem Biophys Res Commun. 2008 Dec 5;377(1):93-7
references.pmid: 18823943
references.citation: Science. 1993 Aug 27;261(5125):1182-4
references.pmid: 7689250